Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 936 trials

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Solid Tumors: DO-2 Drug Study

We are testing a new drug called DO-2 for patients with advanced or hard-to-treat solid tumors. The study aims to understand its safety and how the body processes it.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Refractory Solid Tumors>2 yearsSafety phase (I)Oncology

Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

Cystic Fibrosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPulmonology

Dobutamine for Very Preterm Infants with Low Blood Flow

We are studying the lowest effective dose of dobutamine to help improve blood flow in very preterm infants. The trial also looks at how well the treatment works and its safety during the first few days after birth.

Neonates with Haemodynamic Insufficiency>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCardiologyPediatrics

HER2-Positive Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan Study

We are investigating a new treatment combining Trastuzumab Deruxtecan with immunotherapy and chemotherapy for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer. The study aims to evaluate the safety and tolerability of this approach.

HER2 Positive Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: AZD9574 Treatment Study

We are studying the safety and early effectiveness of AZD9574, both alone and with other cancer therapies, for patients with advanced solid tumors. This research aims to improve treatment options for those facing these challenging conditions.

Advanced Ovarian, Breast, Pancreatic, or Prostate CancerHER2+ Metastatic Solid TumorsAdvanced Unresectable or Metastatic Solid TumorsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

ASP1570 for Advanced Solid Tumors

We are studying a new treatment, ASP1570, alone and with pembrolizumab for adults with advanced solid tumors. The trial aims to evaluate safety, tolerability, and potential anti-tumor effects.

Advanced Solid TumorsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Lung Cancer: Avutometinib and Sotorasib Study

We are testing a combination of two medications for patients with KRAS G12C mutant non-small cell lung cancer. The goal is to find the best dose and see how well it works and how safe it is.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Innovative Cell Therapy for Autoimmune Xerostomia

We are studying a new treatment using fat-derived cells for patients with autoimmune xerostomia. The goal is to see if it can improve symptoms and is safe to use.

Autoimmune Xerostomia1-2 yearsSafety phase (I)Efficacy phase (II)OtolaryngologyRheumatology

Metastatic Colorectal Cancer: Targeted Therapies Study

We are evaluating the safety and effectiveness of new targeted treatments for patients with metastatic colorectal cancer. This study aims to find better options for specific groups of patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Duchenne Muscular Dystrophy: GNT0004 Gene Therapy

We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.

Duchenne Muscular DystrophySafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurologyPediatrics

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

B-Cell Malignancies: SRG-1505 Treatment Study

We are testing a new treatment called SRG-1505 for individuals with mature B-cell malignancies. This study aims to evaluate its safety and appropriate dosage.

B-Cell Neoplasms and Lymphomas>2 yearsSafety phase (I)HematologyOncology

Acute Myeloid Leukemia: MP0533 Treatment Study

We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.

Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Advanced Solid Tumors: XON7 Antibody Study

We are investigating a new antibody treatment for patients with advanced or metastatic solid tumors. This study aims to evaluate its safety and how well it works in treating these cancers.

Advanced or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Peripheral Arterial Disease: New Imaging Agent Study

We are testing a new imaging agent in people with peripheral arterial occlusive disease and healthy volunteers. The goal is to understand its safety and how it distributes in the body.

Critical Limb IschaemiaPeripheral Arterial Occlusive Disease6-12 monthsSafety phase (I)CardiologyInternal Medicine

Advanced Solid Tumors: STAR0602 Treatment

We are testing a new drug, STAR0602, to see if it can help stimulate the immune system in patients with advanced solid tumors that cannot be surgically removed. This study aims to explore its effects on tumors that have spread locally or to other parts of the body.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

TOS-358 for Adults with Solid Tumors

We are testing a new treatment called TOS-358 in adults with solid tumors. This study aims to understand how safe it is and how well it works.

Malignant Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology